8-KEarnings & ResultsLeadership ChangesRegulation FD+1

CVS HEALTH Corp 8-K Report, Financial Results (Jan 5, 2024)

Filed January 5, 2024For Securities:CVS

Summary

CVS Health Corporation (CVS) filed an 8-K on January 5, 2024, providing an update on its financial guidance and announcing executive changes. The company reaffirmed its full-year 2023 guidance for GAAP diluted EPS ($6.37-$6.61) and Adjusted EPS ($8.50-$8.70), expecting the latter to be in the upper half of the range. Full-year 2023 cash flow from operations guidance was also reaffirmed at the upper end of $12.5 billion to $13.5 billion. Looking ahead to 2024, CVS Health anticipates at least $7.26 in GAAP diluted EPS, at least $8.50 in Adjusted EPS, and at least $12.5 billion in cash flow from operations. The company also announced a $3.0 billion accelerated share repurchase transaction and projected at least 800,000 Medicare Advantage membership growth in 2024, driven by stronger-than-expected annual enrollment exceeding expectations.

Key Highlights

  • 1Reaffirmed strong full-year 2023 financial guidance for EPS and cash flow from operations.
  • 2Provided positive 2024 financial outlook with guidance for GAAP EPS, Adjusted EPS, and cash flow.
  • 3Announced a significant $3.0 billion accelerated share repurchase program, indicating confidence in value.
  • 4Projected robust Medicare Advantage membership growth of at least 800,000 in 2024, exceeding expectations.
  • 5Appointed Thomas F. Cowhey as permanent Executive Vice President and Chief Financial Officer.
  • 6Announced the departure of Shawn M. Guertin as CFO and President of Health Services due to family health reasons.
  • 7Appointed Mike Pykosz as President of Health Care Delivery.

Frequently Asked Questions

For full-year 2023, CVS Health reaffirmed its GAAP diluted EPS guidance of $6.37 to $6.61 and Adjusted EPS guidance of $8.50 to $8.70, expecting the latter in the upper half. Cash flow from operations for 2023 is also reaffirmed at the upper end of $12.5 billion to $13.5 billion. For full-year 2024, the company provided guidance of at least $7.26 for GAAP diluted EPS, at least $8.50 for Adjusted EPS, and at least $12.5 billion for cash flow from operations.

CVS Health entered into a $3.0 billion fixed dollar accelerated share repurchase transaction during the fourth quarter of 2023, which became effective on January 3, 2024. This indicates a commitment to returning capital to shareholders.

The company expects at least 800,000 Medicare Advantage membership growth in 2024, exceeding expectations during the annual enrollment period. This growth is attributed to strong new sales and high retention rates for existing members, with a notable increase in new members coming from competitor plans.

Thomas F. Cowhey has been officially appointed as Executive Vice President and Chief Financial Officer, having previously served as interim CFO. Shawn M. Guertin is stepping down from his roles as CFO and President of Health Services due to family health reasons, remaining on leave until May 31, 2024. Mike Pykosz has been appointed as President of Health Care Delivery, also having served in an interim capacity.